News

As of 1 June, we have a new office location in Munich, on Kaulbach Strasse, Schwabing, in the heart of Munich.  Uli Wittmann, who joined us as a Partner on 1 April, along with Ute Pfaller and Henriette März, and other colleagues including Trainee Attorneys and Paralegals. The new office will host a total of […]

Through the ability of Artificial Intelligence, the health care sector can find solutions to effective treatment to cure diseases.   Partner, Adrian Tombling explores why AI is huge for drug research and what impact this could have on the pharmaceutical industry. As AI is created by a computer, it does raise the question, who owns […]

A unanimous decision by the Supreme Court is being hailed as a relief for innovators in the pharmaceutical sector, and confirms that novel and inventive dosage regimes are patentable. Tadalafil (Cialis) is a second in class PDE5 inhibitor for the treatment of erectile dysfunction. This use of tadalafil was first disclosed in EP 0839040 (the […]

Brexit On 23 June 2016, the British people voted in a referendum on whether the UK should remain a member of the European Union. Just under 52% of voters voted to leave the EU, against just over 48% who voted that the UK should remain part of the EU. As a result, the UK began […]

The eagerly awaited Supreme Court judgment in the Warner-Lambert V Generics (UK) and Actavis case has recently been issued (see here), a full nine months after the hearing in February 2018. This is the final step in a saga which has been ongoing for years, and which is of huge importance to the pharmaceutical industry. […]

In a recent decision by the Court of Appeal, Judge Lord Kitchin applied the principles of Actavis vs Eli Lilly (Actavis) to rule upon a patent infringement dispute in Icescape v Ice-World (see here). As previously reported, the landmark Actavis judgement was a 2017 decision from the Supreme Court that essentially changed the decades-old understanding […]